Rifabutin
| Clinical data | |
|---|---|
| Trade names | Mycobutin | 
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a693009 | 
| Pregnancy category | 
 | 
| Routes of administration | By mouth | 
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 85% | 
| Protein binding | 85% | 
| Metabolism | Liver | 
| Elimination half-life | 28 to 62 hours (mean) | 
| Excretion | Kidney and fecal | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.133.627 | 
| Chemical and physical data | |
| Formula | C46H62N4O11 | 
| Molar mass | 847.019 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (verify) | |
Rifabutin (Rfb) is an antibiotic used to treat tuberculosis and prevent and treat Mycobacterium avium complex. It is typically only used in those who cannot tolerate rifampin such as people with HIV/AIDS on antiretrovirals. For active tuberculosis it is used with other antimycobacterial medications. For latent tuberculosis it may be used by itself when the exposure was with drug-resistant TB.
Rifabutin was approved for medical use in the United States in 1992. It is on the World Health Organization's List of Essential Medicines.